Alexandria, VA, April 12, 2001 -- HADRON, INC. (OTC Electronic Bulletin Board: HDRN) today announced the appointment of Dr. Charles L. Bailey to the position of Vice President of Science for its Advanced Biosystems, Inc. subsidiary. Dr. Bailey will provide scientific and management leadership to existing programs, as well as identifying new sources of funding for Advanced Biosystems' research and analysis of defenses against, and treatments for, specific biological agents that may be used in warfare or terrorist attacks.

Dr. Ken Alibek, President of Advanced Biosystems, said, "We are exceptionally pleased that Dr. Charles Bailey is working with us. Dr. Bailey will preside over essential aspects of our programs to develop novel treatments and prophylactic approaches against the many biological threat agents that could be used in biological warfare and terrorism." Sterling Phillips, Hadron President and CEO, added, "Dr. Bailey is well known for his exemplary contributions to our national security, and we are honored that he has joined Hadron to support our biological warfare defense and anti-terrorism programs."

"I am pleased to join Dr. Alibek and his team of excellent scientists," said Dr. Bailey. He added, "I look forward to contributing to the enormous growth we anticipate in these vital scientific and national security programs."

Dr. Bailey is internationally recognized for his twenty-five years of research/development and senior program management experience with the U.S. Army in the field of biological warfare defense. During his career, he worked for more than twelve years at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), where he served as Commander during the Desert Storm War. Dr. Bailey's career also included serving as a senior intelligence officer for the Defense Intelligence Agency. Most recently, Dr. Bailey has worked in the private sector in senior program management positions for SRS Technologies and Battelle Memorial Institute.

Dr. Bailey retired from the U.S. Army as a Colonel. He holds B.S., M.S., and Ph.D. degrees from Oklahoma State University. Dr. Bailey has published more than 70 scientific articles concerning the results of his experiments with a wide variety of infectious agents and toxins.

HADRON specializes in developing intelligence and biodefense solutions in support of our Nation’s security. Hadron focuses on developing innovative technical solutions for the intelligence community, analyzing and supporting defense systems and developing medical defenses and treatments for toxic agents used in biological warfare and terrorism. The Company’s stock trades on the OTC Electronic Bulletin Board under the symbol HDRN. HADRON can be found on the Internet at www.hadron.com. HADRON investor relations can be contacted at (703) 329-9400 or via email at agordon@hadron.com.

Except for the historical information contained herein, this press release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. These forward-looking statements may be identified by reference to a future period by use of forward-looking terminology such as "anticipate," "expect," "could," "intend," "may" and other words of similar nature. There are certain important factors and risks that could cause results to differ materially from those anticipated by the statements contained herein. Such factors and risks include business conditions and growth in the information services, engineering services, software development and government contracting arenas and in the economy in general. Competitive factors include the pressures toward consolidation of small government contracts into larger contracts awarded to major, multi-national corporations; and the Company's ability to continue to recruit and retain highly skilled technical, managerial and sales/marketing personnel. Other risks may be detailed from time to time in the Company's filings with the Securities and Exchange Commission. Hadron undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.